Please select the option that best describes you:
Topics:
Gastrointestinal Cancers • Medical Oncology
How do you approach molecular testing in patients with gastro-esophageal cancers?
Does HER2 or PD1/PDL1 positivity change first line treatment (i.e. preferential enrollment on clinical trials) or do such patients still receiving standard of care chemotherapy?
Answer from: Medical Oncologist at Academic Institution
Her2 is certainly more of a binary situation. Tumors that are Her2 positive (defined as IHC 3+ or IHC 2+ and FISH +ve) benefit from trastuzumab + chemotherapy, while there are no data to support it for tumors that are Her2 negative (IHC 0/1 or IHC 2+ and FISH -ve).
So, Her2 positive tumors should a...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
Yes for HER2There is only evidence to show benefit in first-line setting with the addition of trastuzumab. “Patients with HER2 3+ by IHC benefit most with trastuzumab. And some can live a very long time, like, 12 and 13 years” as per Jaffer A. Ajani, M.D at MDAH, so clearly there is a lo...